¡¾ÌáÒªÐÎò¡¿ÔÚ·ÊÅÖ¼°Ïà¹Ø´úлÐÔ¼²²¡³ÉΪȫÇòÐÔ¿µ½¡Ìôսȷµ±Ï£¬97¹ú¼Ê£¨ÒÔϼò³Æ¡°97¹ú¼Ê¡±£©´«À´Õñ·ÜÈËÐĵÄÐÂÎÅ£¡Æä×ÔÖ÷Ñз¢µÄÁ¢ÒìС·Ö×Ó»·ëÄÒ©ÎMCR»·ëÄ£©£¬ÔÚÕë¶ÔDB/DB·ÊÅÖСÊóÄ£×ÓµÄÁÙ´²Ç°Ñо¿ÖУ¬Õ¹ÏÖ³öÓÅÓÚÏÖÓÐÃ÷ÐÇÒ©ÎïGLP-1¶àëĵļõÖØÐ§¹û£»ÍŽáÆä¶Ô¼¡ÈâµÄ¼á³Ö×÷Óã¬ÒÔ¼°¶ÔѪÌÇ¡¢ÑªÖ¬µÈ´úлָ±êµÄ×ۺϵ÷Àí×÷Óã¬ÓÐÍû´øÀ´²î±ð»¯µÄÁÙ´²Ñ¡Ôñ¡£
¡¾ÌáÒªÐÎò¡¿ÔÚ·ÊÅÖ¼°Ïà¹Ø´úлÐÔ¼²²¡³ÉΪȫÇòÐÔ¿µ½¡Ìôսȷµ±Ï£¬97¹ú¼Ê£¨ÒÔϼò³Æ¡°97¹ú¼Ê¡±£©´«À´Õñ·ÜÈËÐĵÄÐÂÎÅ£¡Æä×ÔÖ÷Ñз¢µÄÁ¢ÒìС·Ö×Ó»·ëÄÒ©ÎMCR»·ëÄ£©£¬ÔÚÕë¶ÔDB/DB·ÊÅÖСÊóÄ£×ÓµÄÁÙ´²Ç°Ñо¿ÖУ¬Õ¹ÏÖ³öÓÅÓÚÏÖÓÐÃ÷ÐÇÒ©ÎïGLP-1¶àëĵļõÖØÐ§¹û£»ÍŽáÆä¶Ô¼¡ÈâµÄ¼á³Ö×÷Óã¬ÒÔ¼°¶ÔѪÌÇ¡¢ÑªÖ¬µÈ´úлָ±êµÄ×ۺϵ÷Àí×÷Óã¬ÓÐÍû´øÀ´²î±ð»¯µÄÁÙ´²Ñ¡Ôñ¡£
ÔÚ·ÊÅÖ¼°Ïà¹Ø´úлÐÔ¼²²¡³ÉΪȫÇòÐÔ¿µ½¡Ìôսȷµ±Ï£¬97¹ú¼Ê£¨ÒÔϼò³Æ“97¹ú¼Ê”£©´«À´Õñ·ÜÈËÐĵÄÐÂÎÅ£¡Æä×ÔÖ÷Ñз¢µÄÁ¢ÒìС·Ö×Ó»·ëÄÒ©ÎMCR»·ëÄ£©£¬ÔÚÕë¶ÔDB/DB·ÊÅÖСÊóÄ£×ÓµÄÁÙ´²Ç°Ñо¿ÖУ¬Õ¹ÏÖ³öÓÅÓÚÏÖÓÐÃ÷ÐÇÒ©ÎïGLP-1¶àëĵļõÖØÐ§¹û£»ÍŽáÆä¶Ô¼¡ÈâµÄ¼á³Ö×÷Óã¬ÒÔ¼°¶ÔѪÌÇ¡¢ÑªÖ¬µÈ´úлָ±êµÄ×ۺϵ÷Àí×÷Óã¬ÓÐÍû´øÀ´²î±ð»¯µÄÁÙ´²Ñ¡Ôñ¡£
Ò»¡¢¾ªÑ޵ļõÖØÊý¾Ý
DB/DBСÊóÊÇÑо¿·ÊÅÖºÍ2ÐÍÌÇÄò²¡µÄ¾µä¶¯ÎïÄ£×Ó£¬ÆäÓÉÓÚ»ùÒòÍ»±äµ¼ÖÂÊÝËØÊÜÌ幦ЧȱÏÝ£¬ÌåÏÖ³öÑÏÖØµÄ·ÊÅÖ¡¢¸ßѪÌǺʹúлÔÓÂÒµÈÖ¢×´¡£ÔÚ97¹ú¼Ê¿ªÕ¹µÄÕâÏîÁÙ´²Ç°Ñо¿ÖУ¬¹«Ë¾×ÔÑеÄС·Ö×Ó»·ëÄÕ¹ÏÖ³öÓÅÒìµÄ¼õÖØÐ§¹û¡£
ÊÔÑéЧ¹ûÏÔʾ£¬¾ÓÉΪÆÚ8ÖܵÄÖÎÁÆ£¬Óë¿Õȱ±ÈÕÕ×éDB/DBСÊóÏà±È£¬MCR»·ëĽϸ߼ÁÁ¿×éµÄСÊóµÄÌåÖØÏ½µ·ù¶ÈԼΪGLP-1¶àëÄ×éµÄ1.25±¶£¬Ê¹DB/DBСÊóµÄÌåÖØÔöÌíÇ÷ÊÆÏÔ×Å·Å»º£¬¿¿½ü¿µ½¡±ÈÕÕ×éˮƽ¡£
¶þ¡¢¶àÏî´úлָ±êÖÜÈ«¸ÄÉÆ
MCR»·ëĽϸ߼ÁÁ¿×éÔÚ¸ÄÉÆ¸ÊÓÍÈýõ¥£¨TG£©¡¢¸ßÃܶÈÖ¬ÂѰ׵¨¹Ì´¼£¨HDL-C£©¡¢ÑªÌÇ¡¢ÄòÌÇˮƽ·½Ã棬ͬÑùÌåÏÖÓÅÒ죺
1.TGˮƽ£ºÏÔÖø½µµÍDB/DBСÊóµÄTGˮƽ£¬ÓÅÓÚGLP-1¶àëÄ×飻
2.HDL-Cˮƽ£ºÏÔ×ÅÉý¸ß£¬ÓÅÓÚGLP-1¶àëÄ×飻ÓÐÖúÓÚ½µµÍ¶¯ÂöÖàÑùÓ²»¯Î£º¦£»
3.ѪÌÇˮƽ£ºÖÎÁÆ6ÖܵĽµµÍѪÌÇŨ¶ÈˮƽÓëGLP-1¶àëÄ×é¿¿½ü£»
4.ÄòÌÇˮƽ£ºÖÎÁÆ8Öܽ«ÄòÌÇˮƽ´Ó»ùÏß½µÖÁÒ»°ë£»
5.ÌÇ»¯ÑªºìÂѰף¨HbA1c£©£ºÓëÄ£×Ó×éÏà±È£¬HbA1cϽµ·ù¶È´ïÔ¼1/3¡£
|ÍŽáDZÁ¦
ÖµµÃÒ»ÌáµÄÊÇ£¬97¹ú¼ÊÒÑ¿ªÕ¹ÁË»·ëÄÓëGLP-1ÀàÒ©ÎÈçGLP-1¶àëÄ£©ÍŽáʹÓõÄÑо¿£¬Ð§¹ûÏÔʾÔÚÒûʳÓÕµ¼µÄ·ÊÅÖСÊóÄ£×ÓÖУ¬Á½ÕßÔÚ¼õÖØÐ§¹û¼°¼¡Èâ±£»¤·½Ãæ¾ßÓÐÃ÷È·µÄÐͬЧӦ£º
1.Ðͬ¼õÖØ£ºÁªÊÊÓÃÒ©×éÌåÏÖ³ö¸üÏÔÖøµÄ¼õÖØÐ§¹û£¬ÓÅÓÚµ¥Ò©ÖÎÁÆ£»
2.ïÔ̼¡ÈâÁ÷ʧ£º»·ëÄÔÚÁªÓÃÖÐÓÐÓûº½âGLP-1ÀàÒ©Îï´øÀ´µÄ¼¡ÈâÁ÷ʧÎÊÌ⣬Ìá¸ßÕûÌåÖÎÁÆÇå¾²ÐÔ¡£
Èý¡¢¶à°ÐµãÐͬ×÷Óãº
»·ëĵÄÁ¢Òì»úÖÆ
MCR»·ëÄÖ®ÒÔÊÇÄܹ»ÔÚ¼õÖØ¼°ÆäËû´úлָ±êÉÏÈ¡µÃÔÆÔÆÓÅÒìµÄЧ¹û£¬ÓëÆäÆæÒìµÄ×÷ÓûúÖÆÃܲ»¿É·Ö¡£×÷ΪһÖÖС·Ö×Ó»·ëÄÒ©ÎÄܹ»Í¬Ê±¾«×¼×÷ÓÃÓÚMC4RºÍMC1RÁ½¸öÒªº¦°Ðµã£¬Í¨¹ý¶à°ÐµãÐͬ×÷Óã¬Ê©Õ¹Æä׿ԽµÄ´úлµ÷Àí¹¦Ð§¡£
|¼¤»îMC4R£ºÒÖÖÆÊ³Óû£¬Ôö½øÖ¬·¾ÆÊÎö
MC4RÊÇÖÐÊàÉñ¾ÏµÍ³µ÷¿ØÄÜÁ¿Æ½ºâµÄÒªº¦ÊÜÌå¡£97¹ú¼ÊMCR»·ëÄ×÷ΪMC4R¼¤¶¯¼Á£¬Äܹ»Ôö½øÖ¬·¾ÆÊÎö£¬ÒÖÖÆÖ¬·¾ÌìÉú£»Ôö½ø°×ɫ֬·¾×éÖ¯ºÖ±ä£»Ìá¸ßÒȵºËØÃô¸ÐÐÔ£»ÔÚ²»ÏÔÖøÒÖÖÆÊ³ÓûµÄÌõ¼þÏÂʵÏÖ¼õÖ¬£¬×èÖ¹Ñáʳ¸±×÷ÓÃ1¡£

|¼¤»îMC1R:¿¹Ñ×ÃâÒßµ÷Àí£¬»Ö¸´ÊÝËØÃô¸ÐÐÔ
MC1RÖ÷Òª¼ÓÈëÃâÒßµ÷ÀíºÍÑ×Ö¢·´Ó¦¡£Í¨¹ý¼¤»îMC1R£¬Äܹ»ÏÔÖø¸ÄÉÆÌåÄÚÑ×֢΢ÇéÐΣ¬½µµÍÑ×Ö¢Òò×Ó£¨°üÀ¨IL-1, TNF-a, IL-6, IL-8, and IL-12, iNOSµÈ£©µÄ±í´ï´Ó¶ø»Ö¸´ÊÝËØÃô¸ÐÐԺ͵÷ÀíÃâÒß·´Ó¦£¬¶Ô×ÔÉíÃâÒßÐÔ¼²²¡¾ßÓÐDZÔÚÖÎÁƼÛÖµ2¡£

ËÄ¡¢ÁÉÀ«µÄÓ¦ÓÃÔ¶¾°£º
´úлÔÓÂÒÓë×ÔÉíÃâÒß˳Ӧ֢
»ùÓÚMCR»·ëÄÔÚÁÙ´²Ç°Ñо¿ÖÐÕ¹ÏÖ³öµÄ׿Խ¼õÖØÐ§¹ûºÍ¶àϵͳ´úл¸ÄÉÆ×÷Óã¬97¹ú¼Ê¶ÔÆäδÀ´ÔÚ´úлºÍ×ÔÃâÁìÓòÖеÄÓ¦ÓÃÔ¶¾°³äÂúÐÅÐÄ¡£
´úл×ÛºÏÕ÷¼°Æä²¢·¢Ö¢·½Ã棬MCR»·ëIJ»µ«ÄܼõÖØ£¬»¹ÄÜͬ²½¸ÄÉÆÑªÌÇ¡¢ÑªÖ¬¡¢HbA1c¡¢ÄòÌǵȶàÏîÖ¸±ê£¬¶Ô2ÐÍÌÇÄò²¡¡¢·Ç¾Æ¾«ÐÔÖ¬·¾ÐԸβ¡¡¢¸ßѪѹ¡¢¶¯ÂöÖàÑùÓ²»¯µÈ´úл×ÛºÏÕ÷×é·ÖÖ®Ò»»ò¶àÏî¾ßÓиÉԤDZÁ¦¡£
×ÔÉíÃâÒßÓëÑ×Ö¢Ïà¹Ø¼²²¡·½Ã棬ÓÉÓÚÆä¾ß±¸ÏÔÖøµÄ¿¹Ñ׺ÍÃâÒßµ÷Àí×÷Óã¬Î´À´ÓÐÍûÍØÕ¹ÖÁÀà·çʪÐÔÊàŦÑ×£»ÂýÐÔÉö²¡£¨CKD£©£»ÌÇÄò²¡Éö²¡£¨DN£©µÈ˳Ӧ֢¡£
½ÓÏÂÀ´£¬¹«Ë¾½«¼ÌÐøÍÆ¶¯¶àëÄÐÂÒ©µÄÁÙ´²Ç°Ò©ÀíѧºÍ¶¾ÀíѧÑо¿£¬ÕùÈ¡ÔçÈÕ½«ÐÂÒ©ÍÆÏòÁÙ´²½×¶Î£¬ÔÚÒÑÊÚȨµÄרÀû¼Ó³ÖÏ£¬¿ìËÙ½«²î±ð»¯µÄºÃÒ©´ø¸øÓµÓÐÏà¹ØÖÎÁÆÐèÇóµÄ»¼ÕßȺÌå¡£
ÎÄÕÂȪԴÓÚҩʱ´ú¹«ÖÚºÅ
²Î¿¼ÎÄÏ×
1. Wen, X., Zhang, B., Wu, B., Xiao, H., Li, Z., Li, R., Xu, X., & Li, T. (2022). Signaling pathways in obesity: mechanisms and therapeutic interventions. Signal transduction and targeted therapy, 7(1), 298.https://doi.org/10.1038/s41392-022-01149-x
2. Mun, Y., Kim, W., & Shin, D. (2023). Melanocortin 1 Receptor (MC1R): Pharmacological and Therapeutic Aspects. International journal of molecular sciences, 24(15),12152. https://doi.org/10.3390/ijms241512152
ɨ¶þάÂëÓÃÊÖ»ú¿´
Ïà¹ØÍÆ¼ö